Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common StockLock-Up Agreement • December 9th, 2020 • Rose William • Pharmaceutical preparations
Contract Type FiledDecember 9th, 2020 Company IndustryThis letter, dated as of the date set forth on the signature page hereto, is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and one or more designated representatives (the “Representatives”) of the Underwriters named therein (the “Underwriters”), relating to an underwritten public offering of Class A common stock, $0.001 par value per share (the “Common Stock”), of the Company (the “Offering”).
JOINDER TO VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • September 19th, 2023 • Rose William • Pharmaceutical preparations
Contract Type FiledSeptember 19th, 2023 Company IndustryThis JOINDER TO VOTING AND SUPPORT AGREEMENT is dated as of September 14, 2023 (this “Joinder”), by the Edward Alexander Rose 1999 Trust, a Texas trust (the “Joining Holder”), in connection with that certain Voting and Support Agreement, dated as of July 28, 2023 (the “Voting and Support Agreement”), by and among William E. Rose, Evelyn P. Rose, Evelyn P. Rose Fidelity SEP IRA, Evelyn Potter Rose Survivor’s Trust, Charles Henry Rose 2001 Trust, John William Rose 2002 Trust, Charles E. Gale, Charles E. Gale Fidelity Rollover IRA, Montrose Investments I, L.P. and Montrose Investments GP, LLC (each a “Holder” and collectively the “Holders”), each stockholders of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Parent. Capitalized terms used but not defined herein have the respective meanings assigned to such terms in the Voting and Support
Lock-up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common StockLock-Up Agreement • June 6th, 2016 • Rose William • Pharmaceutical preparations
Contract Type FiledJune 6th, 2016 Company Industry
Lock-up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common StockLock-Up Agreement • June 6th, 2016 • Rose William • Pharmaceutical preparations
Contract Type FiledJune 6th, 2016 Company Industry
THIRD AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • September 19th, 2023 • Rose William • Pharmaceutical preparations
Contract Type FiledSeptember 19th, 2023 Company IndustryPursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Class A Common Stock of Reata Pharmaceuticals, Inc. The undersigned hereby further agree that this Third Amended and Restated Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Third Amended and Restated Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shal
JOINT FILING AGREEMENTJoint Filing Agreement • June 6th, 2016 • Rose William • Pharmaceutical preparations
Contract Type FiledJune 6th, 2016 Company IndustryPursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Class A Common Stock of Reata Pharmaceuticals, Inc. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counte
Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc.Rose William • June 6th, 2016 • Pharmaceutical preparations
Company FiledJune 6th, 2016 Industry
AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • November 14th, 2018 • Rose William • Pharmaceutical preparations
Contract Type FiledNovember 14th, 2018 Company IndustryPursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Class A Common Stock of Reata Pharmaceuticals, Inc. The undersigned hereby further agree that this Amended and Restated Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Amended and Restated Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed
SECOND AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • August 24th, 2023 • Rose William • Pharmaceutical preparations
Contract Type FiledAugust 24th, 2023 Company IndustryPursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Class A Common Stock of Reata Pharmaceuticals, Inc. The undersigned hereby further agree that this Second Amended and Restated Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Second Amended and Restated Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed sh